Absci Corporation’s ABSI share price has surged by 5.86%, which has investors questioning if this is right time to sell.

Absci Corp. research and ratings by Barron's. View ABSI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...

Washington’s life sciences industry injected a $41.2-billion impact into the state’s economy in 2023 — a 6.2% gain over 2022 ...

Short interest in Absci Corp (NASDAQ:ABSI) increased during the last reporting period, rising from 18.83M to 20.57M. This put 22.75% of the company's publicly available shares short. Short ...

Life Science Washington, the state's industry trade association, today released its annual Economic Impact Report, revealing a 50% increase in job growth from 2013 to 2023. A top 10 life sciences ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

The agreement comes shortly after AstraZeneca agreed a partnership worth up to $247 million with Absci, and Boehringer Ingelheim forged a wide-ranging alliance with IBM, to apply GenAI approaches ...

Research reports are not currently available for ABSI.